Action Potentials in Neuromuscular Disease Models: Translational Electrophysiology
As ALS programs mature, many teams are looking for earlier, more sensitive readouts of neuromuscular dysfunction than behavioral scores or endpoint histology alone can provide. Electrophysiology-based endpoints—such as compound muscle action potentials (CMAP), motor unit number estimation (MUNE), and repeated stimulation paradigms—offer direct, functional insight into motor neuron health and neuromuscular junction integrity in preclinical SOD1 ALS models.
Join Aaron Fantina-Woblistin, R&D Officer at Scantox Neuro, and Michelle Gibson, Research Applications Specialist at iWorx Systems, for "Action Potentials in Neuromuscular Disease Models: Translational Electrophysiology" on February 11, 2026 | 15:00 CET (9:00 AM EST) followed by a Q&A session.
In this joint webinar, Scantox Neuro and iWorx will walk through a longitudinal B6.SOD1-G93A mouse case study based on their recent white paper, demonstrating how CMAP, MUNE, and repeated stimulation can be implemented in vivo to track neuromuscular dysfunction over time and generate more translational data for drug discovery. Attendees will see how action potentials were recorded from the sciatic nerve–gastrocnemius preparation, how signals were analyzed using the iWorx CMAP system and LabScribe software, and how these readouts differentiated SOD1 mice from wild-type controls across disease stages. The discussion will focus on practical considerations for study design, data acquisition and analysis, and how to integrate electrophysiology endpoints into ALS and neuromuscular pipelines.
Key Learning Objectives
- Understand the rationale for incorporating electrophysiology into SOD1 ALS models—why action potentials, CMAP, MUNE, and repeated stimulation provide direct, functional insight into motor unit health and neuromuscular junction integrity.
- See how translational electrophysiology endpoints are implemented in vivo in B6.SOD1-G93A mice, including longitudinal study design (e.g., 8, 14, and 20-week timepoints) and how CMAP and MUNE track disease progression versus wild-type controls.
- Learn how the iWorx CMAP system and LabScribe Action Potentials Module support these readouts, from stimulation and recording configurations to automated extraction of key waveform parameters (amplitude, latencies, rise time, duration, dV/dt).
- Interpret real ALS data generated in a CRO environment—how CMAP, MUNE, and repeated stimulation differentiate SOD1 from WT mice, and how these changes can be used to evaluate candidate therapeutics and refine efficacy endpoints.
- Identify practical considerations for adding electrophysiology endpoints to your own ALS or neuromuscular studies, whether by collaborating with Scantox Neuro or implementing similar iWorx-based workflows in-house.
Who Should Attend
- Preclinical ALS and neuromuscular researchers.
- Pharmacology and efficacy teams working in neurodegeneration.
- CRO project managers and study directors overseeing neuromuscular or ALS studies.
- Lab managers and electrophysiology core staff responsible for functional readouts.
- Anyone considering adding functional neurophysiology endpoints to rodent models.